(NASDAQ: BDTX) Black Diamond Therapeutics's forecast annual revenue growth rate of -46.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Black Diamond Therapeutics's revenue in 2025 is $70,000,000.On average, 2 Wall Street analysts forecast BDTX's revenue for 2025 to be $3,980,384,450, with the lowest BDTX revenue forecast at $3,980,384,450, and the highest BDTX revenue forecast at $3,980,384,450. On average, 1 Wall Street analysts forecast BDTX's revenue for 2026 to be $1,107,115,503, with the lowest BDTX revenue forecast at $1,107,115,503, and the highest BDTX revenue forecast at $1,107,115,503.
In 2027, BDTX is forecast to generate $1,132,703,689 in revenue, with the lowest revenue forecast at $1,132,703,689 and the highest revenue forecast at $1,132,703,689.